Akeega (niraparib and abiraterone acetate) — United Healthcare
metastatic castration-resistant prostate cancer (mCRPC)
Initial criteria
- Diagnosis of metastatic castration-resistant prostate cancer (mCRPC)
- Deleterious or suspected deleterious BRCA-mutated (BRCAm)
- Used in combination with prednisone
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Akeega therapy
Approval duration
12 months